REG - CRISM Therapeutics - Result of Retail Offer and Additional Placing

CRISM' TherapeuticsAnnouncement

03/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nRSC5098Pa&default-theme=true

RNS Number : 5098P  CRISM Therapeutics Corporation  03 July 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE
REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF
CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR
SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT
DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION,
OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE
OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN
WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE
INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO.
596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT
2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. IN ADDITION, MARKET
SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE
MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN
PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE
PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN
POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE
PUBLIC DOMAIN.

 

 

3 July 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Result of Retail Offer and Additional Placing

Further to the announcement by the Company in respect of the Retail Offer
dated 30 June 2025, CRISM Therapeutics Corporation announces that, following
the closing of the Retail Offer on the BookBuild platform on 2 July 2025, the
Company has raised gross proceeds of £54,021 (the "Retail Offer") by way of a
subscription of 450,176 Retail Offer Shares at the Issue Price of 12 pence per
share.

In parallel with the Retail Offer, the Company announces an additional
placement of 166,666 new ordinary shares of no par value each in the Company
("Additional Placing Shares") at the Issue Price to raise gross proceeds of
£20,000 (the "Additional Placing"), to an existing shareholder who was unable
to participate in the Retail Offer. The gross proceeds of the Placing, the
Additional Placing and the Retail Offer raised, in aggregate, £874,021.

The proceeds of the Retail Offer and Additional Placing, together with the
Placing announced on 30 June 2025 (together the "Proceeds"), will enable the
Company to continue to progress the development of ChemoSeed. Specifically,
the Proceeds will fund CRISM for GMP manufacture of a clinical trial batch of
ChemoSeed, through the MHRA's Clinical Trial Authorisation approval process
and to first patients dosed in CRISM's registration grade Phase 2 clinical
trial in early 2026.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the
Retail Offer Shares and Additional Placing Shares ("Admission"). It is
expected that Admission will become effective and that trading will commence
in the Placing Shares at 8.00 a.m. on or around 8 July 2025, or such later
date as may be agreed between the Company and SP Angel. The Retail Offer
Shares and Additional Placing Shares will rank pari passu with the Company's
existing ordinary shares.

Following Admission, the total issued share capital of the Company will
consist of 39,961,822 ordinary shares. The Company does not hold any ordinary
shares in treasury. Therefore, the total number of voting rights in the
Company is 39,961,822 and this figure may be used by shareholders in the
Company as the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's Disclosure and
Transparency Rules.

Other than where defined, capitalised terms used in this Announcement have the
meanings given to them in the announcements of 30 June 2025.

 

-Ends-

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison / Adam Cowl      Mark Court / Jamie Hooper

 Chris McConville, CSO           Vadim Alexandre / Rob Rees        CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
high-grade glioma, ChemoSeeds can be implanted during surgery thereby
bypassing the blood brain barrier, which prevents other treatments from being
able to reach the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROISSEESEEISEDW